On April 18, 2018, Dr. Alex Matter visited Blueray Biohpharma and gave a seminar titled 'Personalized anticancer drug discovery & development in Asia'.
Dr Alex Matter is CEO of the Experimental Therapeutics Centre since April 2009 and since January 2012 CEO of the newly created D3 platform, A*STAR, Singapore. Previously, he had spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation. Dr. Matter played an important role in the success of several anticancer drugs, including Gleevec/Glivec® .
Shanghai Blueray Biopharma Co.,Ltd.
Contact: Ms Lin
Address: Building 3, No. 576 Libing RD, Pudong New Area, Shanghai , CHINA